Mononuclear cells in myopathies: Quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies

doi:10.1016/S0046-8177(86)80180-0

Human Pathology

Volume 17, Issue 7, July 1986, Pages 704-721

https://doi.org/10.1016/S0046-8177(86)80180-0 Get rights and content

Monoclonal antibodies reactive for B cells, T cells, T-cell subsets, killer (K) and natural killer (NK) cells, and the Ia antigen were used to analyzed mononuclear cell subsets in scleroderma (SD), dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM), Duchenne dystrophy (DD), and normal muscle. The analysis, which was quantitative, was performed according to diagnosis and site of accumulation. Cells at perivascular, perimysial, and endomysial sites of accumulation, and cells focally surrounding and invading nonnecrotic muscle fibers, were analyzed separately. Individual antigens were localized in 2-μm serial sections, or multiple antigens were demonstrated in a given section by sequential paired immunofluorescence. The latter approach allowed the identification of the cell phenotypes in which functional properties are defined by multiple markers, e.g., T8⁺ and T4⁺ cells that are either activated or not activated, T8⁺ cells that are either cytotoxic or suppressor T cells, and K/NK cells of varying maturity and killing capability. The interactions of inflammatory cells of various types with each other and the muscle fiber were further investigated by immunoelectron microscopy. In SD, the findings provide evidence for a cell-mediated immune effector response against a connective tissue and/or vascular element. In DM, the effector response appears to be predominantly humoral. In PM and IBM (but not in DM or SD), there is invasion and destruction of nonnecrotic muscle fibers by cytotoxic T cells, with or without accompanying macrophages. Because T-cell-mediated injury is antigen-and major histocompatibility complex-restricted, clones of T cells must have been sensitized previously to a muscle fiber-associated surface antigen. The identity of the putative antigen (s) remains an important, unsolved question.

References (66)

ReinherzEL et al.
The characterization and function of human immunoregulatory T lymphocyte subsets
Immunol Today
(1981)
GiornoR et al.
Immunochemical characterization of the mononuclear cells infiltrating muscle of patients with inflammatory and noninflammatory myopathies
Clin Immunol Immunopathol
(1984)
PhillipsJH et al.
NKP-15: a monoclonal antibody reactive against purified human natural killer cells and granulocytes
Immunol Lett
(1983)
BrownWJ et al.
The mannose-6-phosphate receptor for lysosomal enzymes is concentrated in cis Golgi cisternae
Cell
(1984)
LiepinsA et al.
Ultrastructural changes during T-lymphocyte-mediated cytolysis
Cell Immunol
(1977)
HughesJT et al.
Ulstrastructural studies in human polymyositis
J Neurol Sci
(1975)
MastagliaFL et al.
Lymphocyte-muscle interactions in vivo and in vitro
J Neurol Sci
(1974)
KleinJ
Immunology. The Science of Self-Nonself Discrimination
MartzE et al.
The mechanism of CTL-mediated killing: monoclonal antibody analysis of the roles of killer and target-cell membrane proteins
Immunol Rev
(1983)
PearsonGR
In vitro and in vivo investigations of antibody-dependent cellular cytotoxicity
Curr Top Microbiol Immunol
(1978)

OrtaldoJR et al.

Heterogeneity of natural killer cells

Ann Rev Immunol

(1984)

ArahataK et al.

Monoclonal antibody analysis of mononuclear cells in myopathies. I. Quantitation of subsets according to diagnosis and site of accumulation and counts of muscle fibers invaded by T cells

Ann Neurol

(1984)

EngelAG et al.

Monoclonal antibody analysis of mononuclear cells in myopathies. II. Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis

Ann Neurol

(1984)

ArahataK et al.

Monoclonal antibody analysis of mononuclear cells in myopathies. III. Immunoelectron microscopic aspects of cell mediated muscle fiber injury

Ann Neurol

(1986)

ArahataK et al.

Monoclonal antibody analysis of the mononuclear cell in the muscle biopsy (abstract)

Ann Neurol

(1982)

ArahataK et al.

Endomysial killer/natural killer (K/NK) cells, T cells, and macrophages (MF) in polymyositis (PM), inclusion body myositis (IBM), and Duchenne dystrophy (DD) (abstract)

Neurology

(1985)

ArahataK et al.

Identification and quantitation of T8⁺ cytotoxic (Tc) and T8⁺ suppressor (Ts) cells in muscle in polymyositis (PM) and inclusion body myositis (IBM) (abstract)

Neurology

(1986)

BresnanMJ et al.

Characterization of T-cell subsets in peripheral blood and muscle in childhood dermatomyositis (abstract)

Ann Neurol

(1981)

RoweDJ et al.

Characterization of polymyositis infiltrates using monoclonal antibodies to human leukocyte antigens

Clin Expo Immunol

(1981)

RoweD et al.

Monoclonal antibodies to human leukocyte antigens in polymyositis and muscular dystrophy

Clin Exp Immunol

(1983)

OlssonT et al.

HLA-DR expression, T lymphocyte phenotypes, OKM1 and OKT9 reactive cells in inflammatory myopathy

Muscle Nerve

(1985)

BohanA et al.

Polymyositis and dermatomyositis

N Engl J Med

(1975)

WhitakerJN

Inflammatory myopathy: a review of etiologic and pathogenic factors

Muscle Nerve

(1982)

ChouSM

Inclusion body myositis: a chronic persistent mumps myositis?

Hum Pathol

(1986)

KamounM et al.

Identification of a human lymphocyte surface protein associated with the Erosette receptor

J Exp Med

(1981)

LedbetterJA et al.

Evolutionary conservation of surface molecules that distinguish T lymphocyte helper/inducer and cytotoxic/suppressor subpopulations in mouse and man

J Exp Med

(1981)

BergmanY et al.

Biosynthesis, glycosylation, and in vitro translation of human T cell antigen Leu-4

J Immunol

(1983)

ReinherzEL et al.

Further characterization of the human inducer T cell subset defined by monoclonal antibody

J Immunol

(1979)

ReinherzEL et al.

Separation of functional subsets of human T cells by a monoclonal antibody

Proc Natl Acad Sci USA

(1979)

BallEJ et al.

Cell-mediated cytotoxicity against HLA-D-region products expressed in monocytes and B lymphocytes. IV. Characterization of effector cells using monoclonal antibodies against human T-cell subsets

Immunogenetics

(1982)

ReinherzEL et al.

Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage

Proc Natl Acad Sci USA

(1980)

ReinherzEL et al.

A monoclonal antibody reactive with the human cytotoxic/suppressor T cell subset previously defined by a heteroantiserum termed TH₂

J Immunol

(1980)

LandayA et al.

Characterization of a phenotypically distinct subpopulation of Leu-2⁺ cells that suppress T cell proliferative responses

J Immunol

(1983)

Cited by (267)

Myositis with prominent B cell aggregates may meet classification criteria for sporadic inclusion body myositis
2023, Neuromuscular Disorders
The objective of this study was to report the clinical, serological and pathological features of patients with autoimmune myositis other than dermatomyositis, who displayed both muscle weakness on physical examination and prominent B cell aggregates on muscle pathology, defined as ≥ 30 CD20+ cells/aggregate. Specifically, the presence of a brachio-cervical inflammatory myopathies or a sporadic inclusion body myositis (sIBM) phenotype was recorded. Over a three-year period, eight patients were identified from two university neuropathology referral centers. Seven of 8 (88%) patients had an associated connective tissue disease (CTD): rheumatoid arthritis (n=3), systemic sclerosis (n=2), Sjögren's syndrome (n=1) and systemic lupus erythematosus (n=1), while one patient died on initial presentation without a complete serological and cancer investigation. A brachio-cervical phenotype, i.e. neck weakness, proximal weakness more than distal and shoulder abduction weakness greater than hip flexors, was seen in two patients (25%), while one patient had both proximal and diaphragmatic weakness. In contrast, an IBM-like clinical phenotype was seen in the last five patients (63%), who either had finger flexor weakness and/or quadriceps weakness ≤ 4 on the manual muscle testing MRC-5 scale. Although these 5 patients met at least one set of classification criteria for sIBM, an integrated clinico-sero-pathological approach argued against a diagnosis of sIBM. In summary, in a weak patient with myositis plus an associated CTD and lymphoid aggregates at muscle pathology, B cell predominant aggregates may represent a morphological biomarker against a diagnosis of sIBM.
Autoimmune inflammatory myopathies
2023, Handbook of Clinical Neurology
The autoimmune inflammatory myopathies constitute a heterogeneous group of acquired myopathies that have in common the presence of endomysial inflammation and moderate to severe muscle weakness. Based on currently evolved distinct clinical, histologic, immunopathologic, and autoantibody features, these disorders can be best classified as dermatomyositis, necrotizing autoimmune myositis, antisynthetase syndrome-overlap myositis, and inclusion body myositis. Although polymyositis is no longer considered a distinct subset but rather an extinct entity, it is herein described because its clinicopathologic information has provided over many years fundamental information on T-cell-mediated myocytotoxicity, especially in reference to inclusion body myositis. Each inflammatory myopathy subset has distinct immunopathogenesis, prognosis, and response to immunotherapies, necessitating the need to correctly diagnose each subtype from the outset and avoid disease mimics. The paper describes the main clinical characteristics that aid in the diagnosis of each myositis subtype, highlights the distinct features on muscle morphology and immunopathology, elaborates on the potential role of autoantibodies in pathogenesis or diagnosis , and clarifies common uncertainties in reference to putative triggering factors such as statins and viruses including the 2019-coronavirus-2 pandemic. It extensively describes the main autoimmune markers related to autoinvasive myocytotoxic T-cells, activated B-cells, complement, cytokines, and the possible role of innate immunity. The concomitant myodegenerative features seen in inclusion body myositis along with their interrelationship between inflammation and degeneration are specifically emphasized. Finally, practical guidelines on the best therapeutic approaches are summarized based on up-to-date knowledge and controlled studies, highlighting the prospects of future immunotherapies and ongoing controversies.
Inclusion body myositis
2018, Bulletin de l'Academie Nationale de Medecine
La myosite à inclusions sporadique survient en moyenne au début de la soixantaine et touche trois hommes pour une femme. C’est une myopathie lentement évolutive, handicapante. Phénotypiquement, la maladie touche exclusivement la musculature volontaire et ne comprend pas d’autre atteinte viscérale. Il s’agit une myopathie axiale (camptocormie, trouble de la déglutition) et des ceintures (notamment des quadriceps), mais aussi de la musculature distale (notamment des fléchisseurs des poignets et des doigts). Ces atteintes sont bilatérales et asymétriques. Aux membres supérieurs, le côté dominant est souvent plus longtemps préservé. La présentation clinique est très évocatrice et le diagnostic est affirmé par la biopsie musculaire qui retrouve des infiltrats inflammatoires endomysiaux (la myosite) et des dépôts amyloïdes généralement à proximité de vacuoles (les inclusions). Il y a débat à ce jour pour savoir si cette maladie est originellement de nature auto-immune ou dégénérative. Quoi qu’il en soit, les immunosuppresseurs habituels (corticoïdes, azathio-prine, méthotrexate) ou les immunoglobulines polyvalentes ont fait la preuve de leur inefficacité voire de leur effet délétère. En attendant les résultats des essais thérapeutiques, seul le maintien d’une certaine activité physique (kinésithérapie motrice, autoprogramme, etc.) ralentit la vitesse de progression de la maladie.
The inclusion body myositis starts generally at the beginning of the 6th decade of life and affects 3 men for a woman. It is a slowly progressive debilitating myopathy. Phenotypically, the disease involves the voluntary muscles only, respecting the other organs. Patients present axial weakness (camptocormia, swallowing disorders), limb girdle myopathy (notably of the quadriceps), but also distal myopathy with notably a marked weakness of the handgrip. These lesions are bilateral but asymmetric. At the upper limbs, the dominant side is often preserved for longer. The clinical phenotype is very suggestive, but the definite diagnosis is given by the muscle biopsy, which shows inflammatory infiltrates (the myositis) and amyloid deposits in or near by rimmed vacuoles (the inclusion bodies). There is still a debate to know if the disease is originally auto-immune or degenerative. Nevertheless, the conventional immunosuppressants (corticosteroids, azathioprine, methotrexate…) or the polyvalent immunoglobulins are generally ineffective or can even aggravate the muscle weakness. Pending the results of the randomized controlled ongoing trials, the only way to delay disease progression is to maintain regular physical activity by any kind of soft exercises (physiotherapy, auto-program, gym…).
Pathophysiology of different inflammatory myopathies
2018, Bulletin de l'Academie Nationale de Medecine
L’analyse anatomopathologique des myopathies inflammatoires peut offrir une multitude d’informations sur le diagnostic, mais aussi la pathogénie des différentes entités. Les méthodes d’histologie modernes sont parfaitement complémentaires des approches moléculaires d’analyse dites ‘large scale’ ou ‘omics’ qui peuvent aider à détecter des voies de pathogénie. Ces différentes voies peuvent indiquer le regroupement ou alors la distinction de certains sous-types de myosites. Il est aujourd’hui possible de définir des items qui caractérisent des sous-groupes de myosites selon certaines caractéristiques physiopathologiques. Cette approche permet de distinguer plus précisément les myosites sur le plan pathologique. Cela permet aussi de relier l’anatomopathologie aux auto-anticorps spécifiques des myosites et d’étudier leurs rôles dans le tissu musculaire.
Ainsi, on peut distinguer cinq sous-groupes : les dermatomyosites, les myosites associées aux syndromes des anti-synthétases, plusieurs formes de myopathies nécrosantes autoimmunes, la myosite à inclusions et les myosites non-spécifiques.
The morphological analysis of inflammatory myopathies offers a multitude of information concerning the pathogenicity of different entities. Modern histological and morphological methods are perfectly complementary with molecular approaches like large scale analyses and so called ‘omics’ which can help to detect pathogenic pathways that in turn may help to group together or separate certain forms of myositis from each other. Today it is possible to define features that characterize subgroups of myositis according to certain pathophysiological characteristics, which are more precise than previous analyses. This approach permits to differentiate different forms of myositis more precisely and also offers the possibility to link morphological analyses to auto-antibody studies and to explore their role in the skeletal muscle tissue. In this sense, we differentiate between five subgroups of dermatomyositis, myositis associated with anti-synthetase syndromes, several forms of necrotizing autoimmune myopathies, inclusion body myositis and non-specific myositis.
Altered chemokine receptor expression in the peripheral blood lymphocytes in polymyositis and dermatomyositis
2017, Cytokine
Citation Excerpt :
Despite the similarity, there are some marked differences between them. In PM, the perivascular infiltration in muscle biopsies is composed predominantly of CD8+ T cells and macrophages [4,5], whereas inflammatory infiltration in DM mainly consist of CD4+ T cells as well as B cells and macrophages [6,7]. CD4+ T cells are also the predominant component of infiltrating cells in the skin lesions of DM, and both Th1 and Th2 cells were found in the infiltration [8].
To examine the expression of chemokine receptors in different peripheral blood T-cell subsets in patients with polymyositis (PM) and dermatomyositis (DM).
We used flow cytometry to measure the frequencies of chemokine receptors CXCR3 and CCR4 expression in the CD4⁺ or CD8⁺ lymphocytes. Enzyme linked immunosorbent assays were also used to measure the concentrations of C-X-C motif chemokine 10 (CXCL10), thymus and activation regulated chemokine (TARC) and macrophage derived chemokine (MDC).
Comparing to 20 healthy controls, %CD4⁺CXCR3⁺ and %CD8⁺CXCR3⁺ T cells significantly decreased in 33 DM patients, and %CD8⁺CXCR3⁺ cells decreased in 24 PM patients, but %CD4⁺CCR4⁺ and %CD8⁺CCR4⁺ cells did not significantly change in both the PM and DM patients. Accordingly, the Th1/Th2 polarization, analyzed as the balance obtained after dividing %CD4⁺CXCR3⁺ cells by %CD4⁺CCR4⁺ cells, showed a significant reduction in DM. The serum concentration of CXCR3⁺ ligand, CXCL10, significantly increased and negatively correlated with circulating %CD4⁺CXCR3⁺ cells in DM patients. There was no significant change of TARC and MDC in PM and DM patients. Furthermore, %CD4⁺CXCR3⁺ cells decreased more severely in the patients with interstitial lung disease.
The present results indicate that the distributions of circulating CXCR3⁺ T-cells differ among the PM and DM cases. Our findings suggest a pathogenic difference between PM and DM.
Intravenous Immunoglobulins as Immunomodulators in Autoimmune Diseases and Reproductive Medicine
2023, Antibodies
Intravenous administration of immunoglobulins has been routinely used for more than 60 years in clinical practice, developed initially as replacement therapy in immunodeficiency disorders. Today, the use of intravenous immunoglobulins (IVIGs) is embedded in the modern algorithms for the management of a few diseases, while in most cases, their application is off-label and thus different from their registered therapeutic indications according to the summary of product characteristics. In this review, we present the state-of-the-art use of IVIGs in various autoimmune conditions and immune-mediated disorders associated with reproductive failure, as approved therapy, based on indications or off-label. IVIGs are often an alternative to other treatments, and the administration of IVIGs continues to expand as data accumulate. Additionally, new insights into the pathophysiology of immune-mediated disorders have been gained. Therefore, the need for immunomodulation has increased, where IVIG therapy represents an option for stimulating, inhibiting and regulating various immune processes.

View all citing articles on Scopus

^**: Supported in part by NIH grant NS 6277 and a research center grant from the Muscular Dystrophy Association.

^*: Received from the Department of Neurology and the Neuromuscular Research Laboratory, Mayo Clinic, Rochester, Minnesota,

^†: Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan

View full text

Mononuclear cells in myopathies: Quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies**

Immunol Today

Clin Immunol Immunopathol

Immunol Lett

Cell

Cell Immunol

J Neurol Sci

J Neurol Sci

Immunology. The Science of Self-Nonself Discrimination

The mechanism of CTL-mediated killing: monoclonal antibody analysis of the roles of killer and target-cell membrane proteins

Immunol Rev

In vitro and in vivo investigations of antibody-dependent cellular cytotoxicity

Curr Top Microbiol Immunol

Heterogeneity of natural killer cells

Ann Rev Immunol

Monoclonal antibody analysis of mononuclear cells in myopathies. I. Quantitation of subsets according to diagnosis and site of accumulation and counts of muscle fibers invaded by T cells

Ann Neurol

Monoclonal antibody analysis of mononuclear cells in myopathies. II. Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis

Ann Neurol

Monoclonal antibody analysis of mononuclear cells in myopathies. III. Immunoelectron microscopic aspects of cell mediated muscle fiber injury

Ann Neurol

Monoclonal antibody analysis of the mononuclear cell in the muscle biopsy (abstract)

Ann Neurol

Endomysial killer/natural killer (K/NK) cells, T cells, and macrophages (MF) in polymyositis (PM), inclusion body myositis (IBM), and Duchenne dystrophy (DD) (abstract)

Neurology

Identification and quantitation of T8+ cytotoxic (Tc) and T8+ suppressor (Ts) cells in muscle in polymyositis (PM) and inclusion body myositis (IBM) (abstract)

Neurology

Characterization of T-cell subsets in peripheral blood and muscle in childhood dermatomyositis (abstract)

Ann Neurol

Characterization of polymyositis infiltrates using monoclonal antibodies to human leukocyte antigens

Clin Expo Immunol

Monoclonal antibodies to human leukocyte antigens in polymyositis and muscular dystrophy

Clin Exp Immunol

HLA-DR expression, T lymphocyte phenotypes, OKM1 and OKT9 reactive cells in inflammatory myopathy

Muscle Nerve

Polymyositis and dermatomyositis

N Engl J Med

Inflammatory myopathy: a review of etiologic and pathogenic factors

Muscle Nerve

Inclusion body myositis: a chronic persistent mumps myositis?

Hum Pathol

Identification of a human lymphocyte surface protein associated with the Erosette receptor

J Exp Med

Evolutionary conservation of surface molecules that distinguish T lymphocyte helper/inducer and cytotoxic/suppressor subpopulations in mouse and man

J Exp Med

Biosynthesis, glycosylation, and in vitro translation of human T cell antigen Leu-4

J Immunol

Further characterization of the human inducer T cell subset defined by monoclonal antibody

J Immunol

Separation of functional subsets of human T cells by a monoclonal antibody

Proc Natl Acad Sci USA

Cell-mediated cytotoxicity against HLA-D-region products expressed in monocytes and B lymphocytes. IV. Characterization of effector cells using monoclonal antibodies against human T-cell subsets

Immunogenetics

Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage

Proc Natl Acad Sci USA

A monoclonal antibody reactive with the human cytotoxic/suppressor T cell subset previously defined by a heteroantiserum termed TH2

J Immunol

Characterization of a phenotypically distinct subpopulation of Leu-2+ cells that suppress T cell proliferative responses

J Immunol

Identification and quantitation of T8⁺ cytotoxic (Tc) and T8⁺ suppressor (Ts) cells in muscle in polymyositis (PM) and inclusion body myositis (IBM) (abstract)

A monoclonal antibody reactive with the human cytotoxic/suppressor T cell subset previously defined by a heteroantiserum termed TH₂

Characterization of a phenotypically distinct subpopulation of Leu-2⁺ cells that suppress T cell proliferative responses